Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Time to vent.

I beg to differ, it is not his fiduciary duty to increase pps, or even enhance shareholder.  Although I understand your frustration, I believe you are confusing fiduciary duties with other managment type activities --- the two can be two different things, with the former being a legally binding obligation for which there is recourse if a breach occurred. 

Proper managment of the company at the directive of the board in order to fulfill the board's goals and objectives - one of which might and should be enhancing shareholder value - is actually Mr. Pohl's job and duty.  If he is not particularly adept at doing this and hence fails in achieving the board's goals, then the board can find someone else.  It does not mean he breached any fiduciary duty whatsoever.

Just trying to point out the clear distinction.  Best

Share
New Message
Please login to post a reply